Leverage our end-to-end PGx solutions for clinical trials

Drug Research Laboratory

Leverage our end-to-end PGx solutions for clinical trials

A trustworthy PGx Laboratory Partner

Pharmacogenomics (PGx) testing is an increasingly important tool for clinical trial enrollment, interpretation of clinical data and retrospective studies. We offer PharmacoScanTM assay, PharmacoFocusTM assay, custom genotyping panel, and next generation sequencing (NGS) services for clinical trials and drug development. RPRD is a recognized leader in precision medicine research and clinical testing, bringing deep expertise and an unparalleled testing and data analysis service to organizations conducting clinical trials and drug development.

Precision Medicine Scientists
  • Fully CLIA-certified diagnostic testing laboratory
  • 100% pass rate on CAP proficiency testing
  • A full portfolio of genetic technology platforms, including next generation sequencing (NGS), microarray, real time PCR, etc.
  • Decades of experience in genomic research and clinical diagnostic testing
  • Compliance with HIPPA standard
  • Industry-leading data security
  • 100% customer satisfaction guaranteed 
Border Image

High Quality Testing Service and Support

We are committed to offer the best quality testing and unparalleled supporting service, using NGS, microarray assays (e.g. PharmacoScanTM , PharmacoFocusTM, UK Biobank assay, etc.), real time PCR, etc.

  • Most comprehensive coverage of PGx genes and alleles
  • Thorough analysis of SNPs, Indels, CNVs, translocations, etc.
  • >99.5% specificity and sensitivity
  • Clinical diagnostic-grade quality safeguarded by robust quality control system
  • Comprehensive PGx microarray analysis and next generation sequencing (NGS)
  • A dedicated project manager supporting the whole project
Border Image

Customized, end-to-end PGx solutions

We offer customized and end-to-end precision medicine solutions by leveraging our decades of experience in genomics translational research and clinical testing. We specialize in high-quality data analysis and clinical interpretation to help our partners develop better therapies for tomorrow. We provide precision medicine consulting services at each stage of a project to help guide our partners during the development process.

Commonly Ordered PGx Genes
Phase I EnzymesPhase II EnzymesTransportersModifiers
P450 enzyme (e.g. CYP2D6, CYP2C9, CYP2C19, CYP3A4)UGT (e.g. UGT1A1, UGT1A8),
GST (e.g. GSTM1, GSTM3),
NAT (e.g. NAT1, NAT2)
SULT (e.g. SULT1A1, SULT1A4),
ABC transporter (e.g. ABCB1, ABCG2)
SLC (e.g. SLCO5A1, SLC6A4),
KCNQ1, CFTR, HBB, etc.

State-of-the-art PGx technologies

We offer comprehensive genomic profiling of clinical trial samples in our CLIA-certified laboratory utilizing our comprehensive genomic profiling tests based on Next Generation Sequencing (NGS) and the GeneTitan microarray platform.


Suite of pharmacogenomics assay
PharmacoScan Assay4,627 markers in 1,191 genes of known PGx value, including copy number (CNV) analysis of high-value genes
PharmacoFocus Assay2,000+ relevant PGx variants in 150 genes covering population diversity, including CNV analysis for high-value genes
UK Biobank Axiom Array820,967 SNPs and indel markers
Axiom Precision Medicine Diversity Arrays>900,000 markers relevant to GWAS research, PGx, health risk, etc.
Axiom Transplant Genotyping Array782,000 SNPs, CNVs and indel markers
Custom Gene PanelCustomizable genes and variants panels
Next Generation Sequencing PanelTargeted NGS panel of genes

PharmacoScan and PharmacoFocus Assays

PharmacoScanTM  and PharmacoFocusTM are ideal genotyping assays for translational researchers in pharma and research organizations looking to understand how genetic variations affect drug absorption, distribution, metabolism, and excretion (ADME).

We can precisely and reproducibly analyze nearly 1,200 genes using PharmacoScanTM and over 150 genes using PharmacoFocusTM.

The assays include detecting copy number variation (CNV) and interrogating predictive markers in complex genes (e.g. CYP2D6).

Unlike other platforms that analyze only the common markers, our comprehensive testing approach presents a more complete view of genotype information that potentially lead to more accurate PGx risk evaluation.

Leverage our End-to-End Solutions Today

To request a quote or to learn more about our capabilities.